MORF Morphic Holding Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Morphic Announces Participation in 2022 RBC Capital Markets Global Healthcare Conference

   WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside chat at the RBC Capital Markets on Wednesday, May 18^that 8:00 AM ET.

   A live webcast of the event will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference.

   About Morphic Therapeutic
   Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases…

   View Full Article
2. 12 May 2022 Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer

   WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key executive appointments. Dr. Bruce Rogers has been named President of Morphic Therapeutic and Dr. Blaise Lippa, has been named Chief Scientific Officer. Dr. Rogers previously served as Morphic's Chief Scientific Officer and Dr. Lippa served as Morphic's Senior Vice President and Head of Molecular Discovery.
   

   "Bruce Rogers has been an invaluable leader on the team that built the MInT discovery platform and has been a tireless champion of a science-driven enterprise focused on patients," commented Praveen Tipirneni…

   View Full Article
3. 04 May 2022 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022

   Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis 

   Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO 2022

   Announced key appointments and advancements in leadership team

   Ended first quarter 2022 with $381 million in cash and equivalents, providing runway through year-end 2024

   WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter of 2022.

   First Quarter 2022 and Recent Corporate Highlights

   • Launched EMERALD-1…

   View Full Article
4. 06 April 2022 Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development

   Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader
   Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy

   WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key leadership appointments. Dr. Brihad Abhyankar has joined Morphic as Vice President of Clinical Development and Aaron Pelta was promoted to Senior Vice President, Business and Corporate Development.

   "Brihad's clinical leadership and expertise, including…

   View Full Article
5. 30 March 2022 Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

   WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel discussion titled "Novel Approaches Tackling Autoimmune Conditions" at the BMO Biopharma Spotlight Series on Inflammation & Immunology on Wednesday April 6^th 2022.
   

   About Morphic Therapeutic
   Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie…

   View Full Article